YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
On August 6, Corvus Pharmaceuticals (NASDAQ:CRVS) held its second-quarter 2026 earnings call, and the story was almost entirely about one molecule. Soquelitinib, the company's oral ITK inhibitor, is now being tested across five different d…
Immuno-oncology specialist Corvus Pharmaceuticals (NASDAQ:CRVS) reported a recent insider buy amid a year of sharp share price gains. On June 11, 2026, David Scott Moore, acquired the direct acquisition of 21,700 common shares via option e…
Key Points David Scott Moore acquired 21,700 common shares for a transaction value of approximately $250,000 on June 11, 2026. This transaction marks Moore's first investment in the business. He has been a director since October. The execu…
Is CRVS a good stock to buy? We came across a bullish thesis on Corvus Pharmaceuticals, Inc. on Biotech Distilled's Substack. In this article, we will summarize the bulls' thesis on CRVS. Corvus Pharmaceuticals, Inc.'s share was trading at…
What happened According to its SEC filing dated May 15, 2026, Adams Street Partners LLC reported selling its entire stake of 223,506 shares in Paymentus Holdings (PAY). The estimated transaction value was $5.88 million, based on the mean c…
Key Points Sold 223,506 shares; estimated trade size $5.88 million (based on quarterly average price) Quarter-end position value decreased by $7.06 million, reflecting share sales and price movement Transaction represented a 2.26% change i…
Key Points Boxer Capital acquired 1,100,000 shares of Corvus Pharmaceuticals in the first quarter; the estimated trade size was $17.55 million. The quarter-end stake is valued at $16.09 million. This was a new position for Boxer.10 stocks…
On May 15, 2026, Boxer Capital Management disclosed a new position in Corvus Pharmaceuticals(NASDAQ:CRVS), acquiring 1,100,000 shares in the first quarter for an estimated $17.55 million based on quarterly average pricing. What happened Ac…
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: BNP Paribas upgraded Apple (AAPL) to Outpe…
June S&P 500 E-Mini futures (ESM26) are up +0.23%, andJune Nasdaq 100 E-Mini futures (NQM26) are up +0.20% this morning as investors take on more risk amid mounting speculation that a deal to end the war between the U.S. and Iran is drawin…
Image source: The Motley Fool. DATE Thursday, March 12, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Chief Financial Officer — Leiv LeaPresident and Chief Executive Officer — Richard A. Miller Need a quote from a Motley Fool analyst? Email pr@fo…
Earnings Call Insights: Corvus Pharmaceuticals (CRVS) Q4 2025 MANAGEMENT VIEW * Leiv Lea, Chief Financial Officer, reported research and development expenses of $9.9 million in Q4 2025, attributing the increase to higher clinical trial and…
Bull statues face a rising 2026 market chart, signaling upbeat stock outlook and gains. Key Points Corvus Pharmaceuticals has nearly tripled in value this year amid optimism that its atopic dermatitis drug candidate will continue to delive…
Shares of Corvus Pharmaceuticals CRVS have skyrocketed 208.8% in a month. The massive stock price rally was observed after the company announced positive results from cohort 4 of an early-stage study of its lead candidate, soquelitinib, in…
We recently published 10 Stocks With Effortless Double-, Triple-Digit Gains. Corvus Pharmaceuticals Inc. (NASDAQ:CRVS) was one of the top performers last week. Corvus Pharmaceuticals soared by 211.8 percent week-on-week to hit a new all-ti…
SOUTH SAN FRANCISCO, Calif., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the closing of an upsized underwritten public offering of 9,085,778 sha…
[Industrial sectors, financial services, food and beverage, banks, consumer goods, stock market information.] Torsten Asmus/iStock via Getty Images Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable e…
SOUTH SAN FRANCISCO, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the pricing of an upsized underwritten public offering of 7,900,677 sha…
(RTTNews) - Corvus Pharmaceuticals, Inc. (CRVS), a clinical-stage biopharmaceutical company, announced that it has initiated a public offering of $150 million of shares of its common stock, including pre-funded warrants of its common stock…
Corvus Pharmaceuticals(NASDAQ:CRVS), an immuno-oncology and dermatology drug developer, closed Tuesday at $21.41, up 165.96%. The stock moved higher after Phase 1 soquelitinib data in atopic dermatitis (eczema) showed strong efficacy and c…
(RTTNews) - Biotech names dominated the after-hours session on Friday, with several companies posting notable gains despite limited news catalysts. GH Research PLC (GHRS) surged the most, climbing 22.36% to $16.20, up $2.96. The sharp move…
Patients in 200 mg BID cohort had median progression free survival of 6.2 months and median overall survival of 28.1 months, comparing favorably to results with other therapies Data supports ongoing registration Phase 3 trial in r/r PTCL,…
Earnings Call Insights: Corvus Pharmaceuticals (CRVS) Q3 2025 MANAGEMENT VIEW * CEO Richard Miller emphasized continued progress in the development of soquelitinib for atopic dermatitis and T cell lymphomas, highlighting the completion of…
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that final data from its Phase 1/1b trial of soquelitinib in patients w…
SOUTH SAN FRANCISCO, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on November 4,…
Trial is evaluating ciforadenant as a potential first line therapy for metastatic renal cell cancer (RCC) in combination with ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) Interim data shows triplet therapy with ciforadenant, ipilimum…
Investing.com -- Momentum in small and mid-cap (SMID) biotechnology has accelerated recently, with investors rewarding companies bringing new mechanisms and dosing advantages to market. Over the past six months, the Nasdaq Biotechnology In…
Corvus Pharmaceuticals, Inc. SOUTH SAN FRANCISCO, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, announced today that David Moore, Executive Vice President…
SOUTH SAN FRANCISCO, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, announced today that David Moore, Executive Vice President, US Operations at Novo Nordi…
Earnings Call Insights: Corvus Pharmaceuticals (CRVS) Q2 2025 MANAGEMENT VIEW * CEO Richard A. Miller stated the company's main focus remains the development of soquelitinib for atopic dermatitis, highlighting "an oral medication featuring…
Corvus Pharmaceuticals Inc (NASDAQ:CRVS [https://www.chartmill.com/stock/quote/CRVS]) reported its second-quarter 2025 financial results, with a narrower-than-expected loss per share, prompting a positive after-hours market reaction. The c…
SAN RAFAEL, Calif., Aug. 1, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that the company has appointed Ian T. Clark to the company's Board of Directors, effective today, August 1, 2025.BioMarin Pharmaceutical…
SOUTH SAN FRANCISCO, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on August 7, 2…
Corvus Pharmaceuticals (CRVS) stock remains "undervalued and compelling" compared with peers like Ap PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Introduction & Market Context Corvus Pharmaceuticals (NASDAQ:CRVS) presented its first quarter 2025 business update on May 8, highlighting promising clinical data for its lead drug candidate soquelitinib in atopic dermatitis. The presentat…
This article summarizes the top insider buys and sells reported on Tuesday, July 1, 2025, for US stocks. Top Insider Buys: Kymera Therapeutics Inc (NASDAQ:KYMR): A group of directors, including Mark N Lampert, collectively purchased $13.9…